Biography & Education

Biography
To provide her patients guidance and support to effectively manage their conditions with better quality of life
Specialties
  • Neurology
Education Background
Medical School: Shanghai Second Medical University
Residency: Washington University School of Medicine, St. Louis, Mo.
Fellowship: Washington University School of Medicine, St. Louis, Mo.
Awards
Wexler Prize and Leonard Prize for Research in MS 2011 Foundation of CMSC scholarship 2012
Languages
  • English
  • Chinese - Mandarin
Professional Associations
American Academy of Neurology
Personal Interests
Music, culture, cooking and gardening

Care Locations

1600 East Jefferson
A Level
Seattle, WA 98122
Fax 206-320-2560
Affiliated Facilities
Accepting New Patients
Accepting Children
Accepting Medicare

Publications

Blog

Ocrelizumab getting fast tracked for primary progressive multiple sclerosis

February 26, 2016
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUS™) for the treatment of people with primary progressive multiple sclerosis (PPMS). There is currently no approved treatment for PPMS - a debilitating form of MS characterized by progressive, worsening symptoms and typically without distinct relapses or periods of remission.

Vitamin D Levels in Multiple Sclerosis and Subclinical Disease Activity

November 20, 2015
Low vitamin D levels are thought as a risk factor for the development of multiple sclerosis (MS). Multiple clinical trials are under way to determine whether vitamin D supplementation can reduce the severity of the disease.

Updated diagnostic criteria for neuromyelitis optica spectrum disorders (NMOSD)

August 27, 2015
Neuromyelitis optica (NMO) is a neuroinflammatory disorder characterized by optic neuritis and extensive myelitis. Like multiple sclerosis (MS), it can have a relapsing remitting disease course. Some of the NMO patients tend to run a more aggressive disease course. Most patients with NMO have Ig G antibodies to the aquaporin-4 water channel (AQP4). In July 2015, experts from International Panel for NMO Diagnosis (Wingerchuk DM et al. Neurology 2015 Jul 14) provided updated consensus recommendations for NMO spectrum disorders (NMOSD). 

Can multiple sclerosis result in premature death?

August 11, 2015
While we often counsel patients that multiple sclerosis (MS) does not often result in death, we have noticed some MS patients with aggressive disease who clearly succumb prematurely. To understand survival in the MS population with a matched cohort from the general population, a population based study is needed to evaluate the association of comorbidity with survival in both populations. 

Research Update: Ganglion Cell Layer Thickness May Predict Clinical Recovery in Acute Optic Neuritis

April 17, 2015
Optic neuritis is a common presentation of MS.  Acute inflammation of the optic nerve can lead to transient swelling of the peripapillary retinal nerve fiber layer (pRNFL). Further injury of axons within the optic nerve may lead to degeneration of the retinal ganglion cell (RGC) layer within the macula. RGC layer thickness has been proposed as a measure of neurodegeneration because it is relatively resistant to confounding inflammation. A study was done to track the changes in the retinal layer during a 6-month period in 27 patients with acute optic neuritis to identify patterns of RGC layer changes.

Copaxone and the Interferon Betas Are Clinically Similar

February 10, 2015
Copaxone and the interferon betas (IFN-β) are both effective treatments for a relapsing form of multiple sclerosis (MS). A new study finds that MS patients followed over 10 years have similar annualized relapse rates (ARR) whether they take Copaxone or one of the interferon betas. This recent study looked at 10 years of data on over 3,000 RRMS patients and found that Copaxone and IFN-β were similarly successful in reducing relapses. In the new study, researchers collected data on 3,326 RRMS patients who were using either IFN-β or Copaxone as their first-ever disease-modifying therapy (DMT) for at least 6 months, and had started treatment within 10 years of their first symptom. To be included in the study, patients also had to have had at least one relapse recorded during the two years leading up to the start of their initial DMT. The researchers looked at ...

Breastfeeding, Disease Modifying Therapies (DMTs), and Postpartum Relapse in Multiple Sclerosis

October 27, 2014
Women with multiple sclerosis (MS) have higher risk of relapse during the postpartum period.  Can exclusive breastfeeding alone prevent relapses? How soon after delivery should disease modifying therapies (DMTs) be reintroduced? Are any DMTs safe to take while breastfeeding?    While disease modifying therapies (DMTs) have been shown generally to reduce relapse rates, none of them are indicated for use during pregnancy and lactation. Therefore, the question of when to restart DMTs postpartum remains a difficult one for physicians counseling MS patients who wish to breastfeed their children.   Trying to predict the risk of relapse for any one individual is very difficult. The risk factors for postpartum attacks include ...

Statin Benefits Secondary Progressive MS

June 11, 2014
No treatments can currently abate the advanced stage of the disease, known as secondary progressive MS, which gradually causes patients to become more disabled. Statins are postulated to have immunomodulatory effects that appear to be independent of their effect on cholesterol. A benefit has been suggested in early multiple sclerosis (MS) based on reduction of magnetic resonance imaging brain lesions.  However, following trials have had inconsistent results. In this multicenter, double-blind study, investigators randomized 140 participants with secondary progressive (SP) MS to 80 mg of simvastatin or placebo daily for 2 years. Participants were 18 to 65 years old, had active progression over the preceding 2 years, and had difficulties ambulating but were not wheelchair bound.  Whole brain atrophy was 43% slower annually in simvastati...

FDA approves 40 mg/mL Copaxone for�3 times a week

March 15, 2014
The U.S. Food and Drug Administration (FDA) has approved the three-times-a-week COPAXONE® 40mg/mL, a new dose of COPAXONE® on Jan 28, 2014.  This new formulation will allow for a less frequent dosing regimen administered by injection for patients with relapsing forms of multiple sclerosis (MS). In addition to the newly approved dose, daily COPAXONE® 20 mg/mL will continue to be available. The FDA approval is based on data from ...

Testosterone is associated with worse disease severity in men with early relapsing onset multiple sclerosis

November 01, 2013
MS and many other autoimmune diseases are less common in men than in women. This is especially true during reproductive years. Sex hormones, including testosterone and estrogen, may be responsible for the difference. It is thought that men with multiple sclerosis may have lower testosterone levels than healthy controls. Dr. Bove and his group assessed the prevalence and clinical associations of hypogonadism in men with recent onset relapsing multiple sclerosis.  Male subjects from the Comprehensive Longitudinal Investigations of MS at the Brigham and Women's Hospital (CLIMB) cohort were included. Hormonal measures included testosterone, the testosterone: estradiol ratio, leutinizing hormone (LH), and free testosterone. Clinical outcomes were collected every 6 months for Expanded Disease Severity Scale (EDSS), and annually for Symbol Digit Modalities test (SDMT). The analysis included 96 men with a mean age of 40 years, disease duration of 4...

Specialties

Services Provided
Clinical Interests
  • Multiple Sclerosis
  • Multiple Sclerosis Rehabilitation
  • Neuroimmunology
  • Neuroradiology

Reviews

Patient Ratings and Comments
About Our Survey

The Patient Rating score is based on responses given during the CAHPS Patient Experience Survey. Responses are measured on a 10-point scale, with 10 being the best score. These scores are then translated to a 5-point scale in order to display results in a 5-star rating. Comments are also gathered from the same survey and displayed in their entirety with the exception of any language that may be considered slander, libel or contain private health information, which will be removed prior to publishing the comments.

4.5 out of 5 (75 Ratings, 20 Comments)

60

02/27/2016
Any poor marks with this initial visit were not related to the intelligence, knowledge, courtesy, or clinical evaluation provided by the provider or associated staff. Rather, my concerns […] revolves around the provider having jumped over some very important steps (in my opinion) when relating to a new patient, with a disease process new to them. Her evaluation, and explanation of my diagnosis were thorough, and concise, but instead of following that with any discussion of expected disease course, and running through the treatment options that were available to me and her opinion as to which treatments she felt would provide the best results for me, she attempted to steer me towards 3 available studies. […] I wish to express my disappointment in this encounter, and the complete sense of frustration at what seemed to be very disjointed and uncoordinated care. […] I felt that […] you have not fully figured out how to utilize your assets, and focus on helping your patients versus studying them. […] In other words, make sure they become comfortable and confident in what you have to offer. […]
100

02/21/2016
We traveled from Alaska for initial appt. I was worried it was going to be a quick 30 min. visit. I think Dr. Q. spent 2 hrs. with us.
100

02/02/2016
I loved her and how she included my husband with my care.
100

12/22/2015
[...] im very happy with her and could not have asked for a kinder dr.
100

12/15/2015
Would Highly Recommend
80

12/09/2015
Overall a very positive experience. no problems or concerns.
100

11/26/2015
Dr Qian was very kind, informative and answered all of my questions.
100

10/17/2015
I have MS and feel my treatment by Dr. Qian is fantastic. She takes the time to discuss everything, answers all my questions and is always helpful. I know if I have any concerns Dr. Qian will address them immediately [...]
80

09/27/2015
I've only seen Dr. Qian twice, so am not completely familiar with her. Her accent is heavy, but I can catch on fairly quickly to what she is saying. She is SUPER friendly and courteous! It will take me a while to gain confidence in her medical abilities - I just haven't had that much time with her as a physician yet to have that. [...] I have totally appreciated how friendly, approachable, and at ease she is during our appts.
90

08/27/2015
I hope I don't ever need to recommend a neurologist who specializes in MS to anyone but if I do, I would recommend Dr. Qian.
100

08/17/2015
Dr. Qian was most compassionate when I described the stress I have gone through about my tiny granddaughters just both being diagnosed to have type one diabetes from Children's Hospital ...
90

07/28/2015
This was my first visit with the doctor and I was impressed by her thoroughness, professionalism and friendliness!
100

07/22/2015
I have just been very pleased with the care I have received at Swedish neurology. I am impressed with the amount of time my doctor spends with me every visit. I always get a very clear prognosis and action plan. Thank you!
80

07/15/2015
A follow-up phone call after hours indicated the doctor was reading through my paperwork carefully.
40

06/01/2015
got a lecture rather than care from Dr. Qian; did not listen to my immediate concerns or make a records request (as I had asked when I made the appointment) from my previous doctor prior to our appointment, consequently she lectured me based on information that was a year old and preliminary
100

05/19/2015
Dr. Qian never seems rushed. I really like that.
100

05/07/2015
[...] Excellent.
100

04/22/2015
I have recommended others to the clinic for conditions other than mine.
100

04/21/2015
Dr Qian is compassionate and understanding.
80

04/16/2015
I love Dr. Qian.